. Author manuscript; available in PMC: 2015 Oct 15.

Published in final edited form as: Clin Cancer Res. 2015 Feb 3;21(8):1869–1876. doi: 10.1158/1078-0432.CCR-14-2424

Table 3. Incidence and risk of infection between cases and controls and between single agent PI3K-AKT-mTOR and combination therapies.

	All grade infection				Grade 3/4 infection
	With infection	Without infection	OR (95% CI)	p	With infection	Without infection	OR (95% CI)	p
Controls	8 (8%)	92 (92%)	-	-	3 (3%)	97 (97%)	-	-
Single agent PAMi	99 (27%)	267(73%)	4.26^* (1.9-9.1)	0.0001	38 (10%)	328 (90%)	3.74^* (1.1-12.4)	0.02
PAMi + Chemotherapy	16 (62%)	9 (38%)	4.79^** (2.0- 11.2)	0.0001	6 (25%)	18 (75%)	2.87^** (1.0-7.6)	0.03
PAMi + MEKi	26 (62%)	16 (38%)	4.38^** (2.2-8.5)	<0.0001	3 (7%)	39 (93%)	0.66^** (0.1-2.2)	0.5

Odds ratio calculated between single agent PI3K-AKT-mTOR inhibitors and control group

^**

Odds ratio calculated between single agent PI3K-AKT-mTOR inhibitors and PI3K-AKT-mTOR inhibitors combination therapies (PAMi+chemotherapy and PAMi+MEKi)